Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.86 |
| ▸ | DRD2 | P14416 | 8/20 | 0.86 |
| ▸ | HRH1 | P35367 | 8/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.70 |
| ▸ | DRD1 | P21728 | 7/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.70 |
| ▸ | HTR2A | P28223 | 6/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | HTR2C | P28335 | 4/20 | 0.70 |
| ▸ | HTR2B | P41595 | 4/20 | 0.70 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.70 |
| ▸ | HTR6 | P50406 | 2/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 7/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metopimazine SCHEMBL49905 | 0.93 | DRD3 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL29462317 | 0.93 | DRD3 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL30038347 | 0.93 | DRD3 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL24570717 | 0.92 | DRD2 (0.86) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL22645258 | 0.91 | DRD3 (0.96) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL22645257 | 0.90 | DRD3 (0.95) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Metopimazine SCHEMBL13724685 | 0.86 | DRD3 (0.87) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| SCHEMBL15857644 | 0.84 | DRD2 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Pipamazine SCHEMBL49665 | 0.83 | DRD2 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A | |
| Pipamazine SCHEMBL30627529 | 0.83 | DRD2 (1.00) | DRD3DRD2HRH1SLC6A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202826-A1 | METHODS FOR TREATING GI TRACT DISORDERS | NEUROGASTRX, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202826-A1 | METHODS FOR TREATING GI TRACT DISORDERS | SLC10A2, HNMT, GIPR | DRD3 297/4885DRD2 160/4885HRH1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.